Title:
TARGET VALIDATION ASSAY
Document Type and Number:
WIPO Patent Application WO2006074292
Kind Code:
A3
Abstract:
An method of determining whether a gene of interest is necessary for a tumor cell to maintain its tumorigenicity is disclosed. The method is useful for validation of cancer therapeutic targets in vivo, using shRNAs and tumor xenografts. The inducible shRNA method operates an in vivo RNAi competition assay.
Inventors:
WENG ZHIGANG (US)
GYURIS JENO (US)
CLARK STEVEN C (US)
GYURIS JENO (US)
CLARK STEVEN C (US)
Application Number:
PCT/US2006/000299
Publication Date:
November 02, 2006
Filing Date:
January 06, 2006
Export Citation:
Assignee:
AVEO PHARMACEUTICALS INC (US)
WENG ZHIGANG (US)
GYURIS JENO (US)
CLARK STEVEN C (US)
WENG ZHIGANG (US)
GYURIS JENO (US)
CLARK STEVEN C (US)
International Classes:
A01K67/00; C12N15/11; C12N15/113; C12N15/63
Domestic Patent References:
| WO2002079419A2 | 2002-10-10 | |||
| WO2005021754A1 | 2005-03-10 |
Other References:
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2004 (2004-11-01), NANDI ASIT K ET AL: "Regulation of PDZ-Binding kinase (PBK) in hematopoietic tumors.", XP002383856, Database accession no. PREV200510266938
STEINER M S ET AL: "ANTISENSE C-MYC RETROVIRAL VECTOR SUPPRESSES ESTABLISHED HUMAN PROSTATE CANCER", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 9, no. 5, 20 March 1998 (1998-03-20), pages 747 - 755, XP009035908, ISSN: 1043-0342
CHIN L ET AL: "FLIPPING THE ONCOGENE SWITCH ILLUMINATION OF TUMOR MAINTENANCE AND REGRESSION", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 16, no. 4, April 2000 (2000-04-01), pages 147 - 150, XP002924262, ISSN: 0168-9525
WU M ET AL: "Genetically engineered human breast tumors in mice", BREAST CANCER RESEARCH AND TREATMENT, vol. 94, no. Suppl. 1, 2005, & 28TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM; SAN ANTONIO, TX, USA; DECEMBER 08 -11, 2005, pages S10, XP009067092, ISSN: 0167-6806
XU L ET AL: "Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor [beta] signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model", CANCER RESEARCH 01 JUL 2005 UNITED STATES, vol. 65, no. 13, 1 July 2005 (2005-07-01), pages 5711 - 5719, XP002383847, ISSN: 0008-5472
TREVINO J G ET AL: "Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model", AMERICAN JOURNAL OF PATHOLOGY 2006 UNITED STATES, vol. 168, no. 3, 2006, pages 962 - 972, XP009067184, ISSN: 0002-9440
STEINER M S ET AL: "ANTISENSE C-MYC RETROVIRAL VECTOR SUPPRESSES ESTABLISHED HUMAN PROSTATE CANCER", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 9, no. 5, 20 March 1998 (1998-03-20), pages 747 - 755, XP009035908, ISSN: 1043-0342
CHIN L ET AL: "FLIPPING THE ONCOGENE SWITCH ILLUMINATION OF TUMOR MAINTENANCE AND REGRESSION", TRENDS IN GENETICS, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 16, no. 4, April 2000 (2000-04-01), pages 147 - 150, XP002924262, ISSN: 0168-9525
WU M ET AL: "Genetically engineered human breast tumors in mice", BREAST CANCER RESEARCH AND TREATMENT, vol. 94, no. Suppl. 1, 2005, & 28TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM; SAN ANTONIO, TX, USA; DECEMBER 08 -11, 2005, pages S10, XP009067092, ISSN: 0167-6806
XU L ET AL: "Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor [beta] signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model", CANCER RESEARCH 01 JUL 2005 UNITED STATES, vol. 65, no. 13, 1 July 2005 (2005-07-01), pages 5711 - 5719, XP002383847, ISSN: 0008-5472
TREVINO J G ET AL: "Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model", AMERICAN JOURNAL OF PATHOLOGY 2006 UNITED STATES, vol. 168, no. 3, 2006, pages 962 - 972, XP009067184, ISSN: 0002-9440
Download PDF:
Previous Patent: OPTICAL FLOW BASED TILT SENSOR
Next Patent: BICYCLIC DIHYDROPYRIMIDINES AS EG5 INHIBITORS
Next Patent: BICYCLIC DIHYDROPYRIMIDINES AS EG5 INHIBITORS